Advertisement
Advertisement
U.S. markets close in 3 hours 1 minute
Advertisement
Advertisement
Advertisement
Advertisement

Forward Pharma A/S (FWP)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
4.5000+0.0300 (+0.67%)
As of 10:34AM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
MACD

MACD

Previous Close4.4700
Open4.4800
Bid4.3300 x 800
Ask4.5100 x 1000
Day's Range4.4800 - 4.5500
52 Week Range4.0200 - 20.3100
Volume706
Avg. Volume6,411
Market Cap31.91M
Beta (5Y Monthly)1.45
PE Ratio (TTM)N/A
EPS (TTM)-0.2710
Earnings DateApr 08, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateSep 12, 2017
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for FWP

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Forward Pharma A/S
    Analyst Report: Biogen Inc.Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
    Rating
    Fair Value
    Economic Moat
    17 days agoMorningstar
View more
  • GlobeNewswire

    Forward Pharma Reports Financial and Operating Results for the Year Ended December 31, 2021

    COPENHAGEN, Denmark, April 08, 2022 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we,” “Forward” or the “Company” and, together with its subsidiaries, the “Group”), today reported consolidated financial results for the year ended December 31, 2021. Our net loss for the year ended December 31, 2021 was $1.9 million, or $0.02 per share, versus a net loss of $6.4 million, or $0.07 per share, for the year ended December 31, 2020. Our research, development, general and administrative costs in

  • Benzinga

    Mid-Day Market Update: Gold Drops 2%; Pliant Therapeutics Shares Jump

    Midway through trading Tuesday, the Dow traded down 0.76% to 35,098.84 while the NASDAQ rose 0.09% to 15,376.87. The S&P also fell, dropping 0.33% to 4,520.38. The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 40,019,200 cases with around 649,110 deaths. India confirmed a total of at least 33,058,840 cases and 441,040 deaths, while Brazil reported over 20,899,930 COVID-19 cases with 583,810 deaths. In total, there were at least 221,163,250 cases o

  • Benzinga

    Mid-Morning Market Update: Markets Open Lower; Avantor To Acquire Masterflex

    Following the market opening Tuesday, the Dow traded down 0.59% to 35,159.50 while the NASDAQ fell 0.05% to 15,355.16. The S&P also fell, dropping 0.35% to 4,519.52. The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 40,019,200 cases with around 649,110 deaths. India confirmed a total of at least 33,058,840 cases and 441,040 deaths, while Brazil reported over 20,899,930 COVID-19 cases with 583,810 deaths. In total, there were at least 221,163,250 c

Advertisement
Advertisement